Alexander J. Muller

Alexander J. Muller

Auto-generated profile, based on publicly available information

Alexander J. Muller

Lankenau Institute for Medical Research, Wynnewood, PA, United States; Drexel University College of Medicine, Philadelphia, PA, United States; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 1990 in Science
Verified
Journal Article
Closed access
PDF file
TLTracy G. Lugo
Tracy G. Lugo
APAnn Marie Pendergast
Ann Marie Pendergast
AMAlexander J. Muller
Alexander J. Muller
OWOwen N. Witte
Owen N. Witte
Oncogenic activation of the proto-oncogene c- abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210 bcr-abl and p185 bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.

13 February 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AMAlexander J Muller
Alexander J Muller
JDJames B DuHadaway
James B DuHadaway
PDP Scott Donover
P Scott Donover
ESErika Sutanto-Ward
Erika Sutanto-Ward
GPGeorge C Prendergast
George C Prendergast

15 January 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
DHDe-Yan Hou
De-Yan Hou
AMAlexander J. Muller
Alexander J. Muller
MSMadhav D. Sharma
Madhav D. Sharma
JDJames DuHadaway
James DuHadaway
TBTinku Banerjee
Tinku Banerjee
DMDavid H. Munn
David H. Munn
Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a number of biological settings. In cancer, IDO activity may help promote acquired tolerance to tumor antigens. The IDO inhibitor 1-methyl-tryptophan is being developed for clinical trials. However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biological properties, and it has been unclear which isomer might be preferable for initial development. In this study, we provide evidence that the d and l stereoisomers exhibit important cell type–specific variations in activity. The l isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell–based assays. However, the d isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte–derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. In vivo, the d isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer. The d isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of d-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice). Taken together, our findings support the suitability of d-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens. [Cancer Res 2007;67(2):792–801]

1 August 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RMRichard Metz
Richard Metz
JDJames B. DuHadaway
James B. DuHadaway
UKUma Kamasani
Uma Kamasani
LLLisa Laury-Kleintop
Lisa Laury-Kleintop
AMAlexander J. Muller
Alexander J. Muller
GPGeorge C. Prendergast
George C. Prendergast
Small-molecule inhibitors of indoleamine 2,3-dioxygenase (IDO) are currently being translated to clinic for evaluation as cancer therapeutics. One issue related to trials of the clinical lead inhibitor, d-1-methyl-tryptophan (D-1MT), concerns the extent of its biochemical specificity for IDO. Here, we report the discovery of a novel IDO-related tryptophan catabolic enzyme termed IDO2 that is preferentially inhibited by D-1MT. IDO2 is not as widely expressed as IDO but like its relative is also expressed in antigen-presenting dendritic cells where tryptophan catabolism drives immune tolerance. We identified two common genetic polymorphisms in the human gene encoding IDO2 that ablate its enzymatic activity. Like IDO, IDO2 catabolizes tryptophan, triggers phosphorylation of the translation initiation factor eIF2α, and (reported here for the first time) mobilizes translation of LIP, an inhibitory isoform of the immune regulatory transcription factor NF-IL6. Tryptophan restoration switches off this signaling pathway when activated by IDO, but not IDO2, arguing that IDO2 has a distinct signaling role. Our findings have implications for understanding the evolution of tumoral immune tolerance and for interpreting preclinical and clinical responses to D-1MT or other IDO inhibitors being developed to treat cancer, chronic infection, and other diseases. [Cancer Res 2007;67(15):7082–7]

19 March 2008 in Immunological Reviews
Verified
Journal Article
Closed access
JKJessica B. Katz
Jessica B. Katz
AMAlexander J. Muller
Alexander J. Muller
GPGeorge C. Prendergast
George C. Prendergast

1 August 2012 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CSCourtney Smith
Courtney Smith
MCMee Young Chang
Mee Young Chang
KPKatherine H. Parker
Katherine H. Parker
DBDaniel W. Beury
Daniel W. Beury
JDJames B. DuHadaway
James B. DuHadaway
AMAlexander J. Muller
Alexander J. Muller
Indoleamine 2,3-dioxygenase (IDO) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies, indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of the impact of IDO on tumorigenesis in physiologic models of primary or metastatic disease is lacking. Investigating the impact of Ido1 gene disruption in mouse models of oncogenic KRAS-induced lung carcinoma and breast carcinoma–derived pulmonary metastasis, we have found that IDO deficiency resulted in reduced lung tumor burden and improved survival in both models. Micro-computed tomographic (CT) imaging further revealed that the density of the underlying pulmonary blood vessels was significantly reduced in Ido1-nullizygous mice. During lung tumor and metastasis outgrowth, interleukin (IL)-6 induction was greatly attenuated in conjunction with the loss of IDO. Biologically, this resulted in a consequential impairment of protumorigenic myeloid-derived suppressor cells (MDSC), as restoration of IL-6 recovered both MDSC suppressor function and metastasis susceptibility in Ido1-nullizygous mice. Together, our findings define IDO as a prototypical integrative modifier that bridges inflammation, vascularization, and immune escape to license primary and metastatic tumor outgrowth. Significance: This study provides preclinical, genetic proof-of-concept that the immunoregulatory enzyme IDO contributes to autochthonous carcinoma progression and to the creation of a metastatic niche. IDO deficiency in vivo negatively impacted both vascularization and IL-6–dependent, MDSC-driven immune escape, establishing IDO as an overarching factor directing the establishment of a protumorigenic environment. Cancer Discov; 2(8); 722–35. ©2012 AACR. Read the Commentary on this article by Novitskiy et al., p. 673. This article is highlighted in the In This Issue feature, p. 653.